Analyzing Apricus Biosciences (APRI) & The Competition
Apricus Biosciences (NASDAQ: APRI) is one of 116 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Apricus Biosciences to similar businesses based on the strength of its profitability, risk, valuation, analyst recommendations, dividends, earnings and institutional ownership.
This is a breakdown of recent recommendations and price targets for Apricus Biosciences and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Apricus Biosciences Competitors||827||3703||6739||182||2.55|
Apricus Biosciences presently has a consensus price target of $4.50, indicating a potential upside of 147.25%. As a group, “Pharmaceuticals” companies have a potential upside of 23.35%. Given Apricus Biosciences’ stronger consensus rating and higher possible upside, research analysts clearly believe Apricus Biosciences is more favorable than its rivals.
Volatility & Risk
Apricus Biosciences has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Apricus Biosciences’ rivals have a beta of 0.90, meaning that their average stock price is 10% less volatile than the S&P 500.
Institutional and Insider Ownership
15.3% of Apricus Biosciences shares are owned by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.6% of Apricus Biosciences shares are owned by insiders. Comparatively, 11.8% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
This table compares Apricus Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Apricus Biosciences Competitors||-2,882.23%||-68.02%||-8.95%|
Valuation and Earnings
This table compares Apricus Biosciences and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Apricus Biosciences||$5.76 million||-$10.05 million||2.68|
|Apricus Biosciences Competitors||$8.20 billion||$2.68 billion||-1.31|
Apricus Biosciences’ rivals have higher revenue and earnings than Apricus Biosciences. Apricus Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Apricus Biosciences rivals beat Apricus Biosciences on 7 of the 12 factors compared.
About Apricus Biosciences
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Receive News & Ratings for Apricus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.